TAG1 and NRG PALLAS: Expanding Partnership to Support Prostate Cancer Patients
TAG1 and NRG PALLAS are expanding their partnership to facilitate European access to the TAG1 lead-212 generator. This collaboration aims to strengthen the isotope supply chain and improve the supply of radiopharmaceuticals to Europe.
The radioisotope Lead-212 (Pb-212) is used as a so-called alpha-emitter. The radioisotope is bound to a peptide, which is absorbed by cancer cells while selectively avoiding other cells in the body. It consequently destroys the cancer cell from within, leaving the surrounding tissue unaffected. The use of alpha-emitters such as Lead-212 (Pb-212) is highly promising in the fight against cancer. The radioisotope is particularly applied in cases of advanced prostate cancer. It is anticipated that it will also find application in the treatment of other forms of cancer in the future. This treatment is known as Targeted Alpha Therapy (TAT).
NRG PALLAS and TAG1 are expanding their existing collaboration with a new multi-year agreement. This agreement focuses on the supply of Radium-224 (a key precursor to Lead-212) for the production of Pb-212 generators for the TAG1 generator, in both the US and Europe. The TAG1 Generator is designed to facilitate the supply of Pb-212 for preclinical and clinical trials involving targeted alpha therapies. Both companies are committed to establishing safe, scalable isotope supply chains and supporting the clinical infrastructure necessary for innovation in radiopharmaceuticals.
The agreement provides new opportunities for radiopharmaceutical developers and research institutions across the continent. By establishing a regional supply of Radium-224, the partnership helps meet the growing demand for these isotopes. This supports the advancement of alpha-therapies in oncology.
“We are proud to deepen our partnership with TAG1 and to support the next chapter of radiopharmaceutical innovation in Europe,” said Maurits Wolleswinkel, CEO of NRG PALLAS. “Ensuring the availability of high-quality Radium-224 is a crucial step in the large-scale production of Lead-212 and helps to further expand targeted alpha therapy globally.”
“This partnership represents a significant step forward in TAG1's mission to expand clinical access to Pb-212,” stated Sumit Verma, CEO and Founder of TAG1. "With access to Radium-224 from NRG PALLAS for both Europe and the US, we are not only facilitating a new market but also strengthening the critical infrastructure."
